Tags : Pfizer Ventures

Original

Missin Therapeutics secures £12 million Series C investment led by

Mission Raises $15m and Expands its Relationship with Pfizer CAMBRIDGE, UK– 6 July 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (“Pfizer”)(NYSE: PFE). […]Read More